Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer Kim A. Margolin, James H. Doroshow, Paul Frankel, Warren Chow, Lucille A. Leong, Dean Lim, Mark McNamara, Robert J. Morgan, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Yun Yen, Neil Kogut, Jeffrey Schriber, Joseph Alvarnas, Susan Stalter Biology of Blood and Marrow Transplantation Volume 11, Issue 11, Pages 903-911 (November 2005) DOI: 10.1016/j.bbmt.2005.07.010 Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Progression-free (PFS) and overall (OS) survival for all 33 patients entered onto the protocol (Kaplan-Meier analysis). Biology of Blood and Marrow Transplantation 2005 11, 903-911DOI: (10.1016/j.bbmt.2005.07.010) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 A, Progression-free survival by IGCCCG risk group at diagnosis. B, Overall survival by IGCCCG risk group at diagnosis. Biology of Blood and Marrow Transplantation 2005 11, 903-911DOI: (10.1016/j.bbmt.2005.07.010) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 A, Progression-free survival by Beyer risk group at the time of protocol entry. B, Overall survival by Beyer risk group at the time of protocol entry. Biology of Blood and Marrow Transplantation 2005 11, 903-911DOI: (10.1016/j.bbmt.2005.07.010) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions